University of Vermont

College of Medicine

Department of Medicine

Pulmonary Disease & Critical Care Medicine

Bio for Charles Irvin, Ph.D.
Charles Irvin, Ph.D.

Charles Irvin, Ph.D.

Professor of Medicine, Pulmonary Medicine
Department of Medicine


Contact Information
E-mail: Charles.Irvin@uvm.edu
Phone:
(802) 656-8928
Office Location:
College of Medicine, Health Science Research Facility, 149 Beaumont Avenue, Room 226, Burlington, VT 05405-0075, USA

Education

1968-1972 B.S. Degree (Biology) Carroll College Waukesha, Wisconsin
1972 - 1978 Ph.D. Degree (Physiology) University of Wisconsin Madison, Wisconsin

Academic Appointments

1973 - 1975 Teaching Assistant Department of Physiology University of Wisconsin Madison, Wisconsin
1975 - 1978 Research Assistant Department of Preventive Medicine University of Wisconsin Madison, Wisconsin
1978 - 1980 Post Doctoral Fellow, NIH-NRSA (HL #05784) Meakins-Christie Laboratory McGill University Montréal, Québec, Canada
1981-1988 Assistant Professor of Medicine Pulmonary Sciences Division University of Colorado Health Sciences Center Denver, Colorado
1981 - 1992 Associate Director Pulmonary Physiology Unit National Jewish Center for Immunology and piratory Medicine Denver, Colorado
1988 - 1995 Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine University of Colorado Health Sciences Center, Denver, Colorado
1992 - 1998 Director Pulmonary Physiology Unit, National Jewish Medical and Research Center Denver, Colorado
1995 -1998 Senior Faculty Member Department of Medicine and Pediatrics National Jewish Medical and Research Center Denver, Colorado
1995 -1998 Professor Department of Medicine Division of Pulmonary Sciences and Critical Care Medicine University of Colorado Health Sciences Center, Denver, Colorado
1999 – 2000 Interim Chief Division of Pulmonary Sciences and Critical Care Medicine
1998 – Present Director Vermont Lung Center Fletcher Allen Healthcare University of Vermont
1998 – Present Professor Department of Medicine Department of Molecular Physiology and Biophysics University of Vermont Burlington, Vermont
2001-present Associate Chair for Research Affairs Department of Medicine

Research Grants

American Lung Association Asthma Clinical Research Center Charles G. Irvin, Principal Investigator (10% effort)2002 – 2004 $1,000,000 (total award)

Merck - Merck & Co. Inc Charles G. Irvin, Principal Investigator 2000 – open $58,174 (total award)

P20 RR15557-01 - National Center for Research Resources (NIH) Center of Biomedical Research Excellence (COBRE)Translational Research in Lung Biology and Disease Charles G. Irvin, Principal Investigator (10% effort)COBRE Administration 9/30/00 – 9/29/05$6,199,452 direct cost. $9,197,900 total cost

P20 RR15557-01 - National Center for Research Resources (NIH) Center of Biomedical Research Excellence (COBRE) Project 4: Elucidation of the role of altered pulmonary proteolysis in the pathogenesis of asthma. Charles G. Irvin, Monitoring Investigator (20% effort)9/30/00 – 9/29/05 $229,091 year 1 direct cost. $1,661,059 total 5 yr. cost

PO1 HL 67004 - National Institutes of Heart, Blood and Lung (NHBLI)Program Project Grant: “Signaling in epithelial injury, proliferation and fibrosis” Principal Investigator: Brooke Mossman, Ph.DProject (2) title: “Signaling in bronchiolar epithelium and airway fibrosis” Prin. Investigator: Charles G. Irvin, Ph.D.(20% effort) 4/01/01 – 3/31/06 $151,161 year 1 direct cost. $793,001 total 5 yr. costs

RO1 HL/EB 67273 - National Heart, Lung and Blood Institute Assessment of Lung Function in Mice PI: Jason H.T. Bates, PhD.,D.Sc Co-Investigator: Charles G. Irvin, Ph.D. (20% effort)12/01/01 – 11/30/04 $225,000 year 1. $1,021,500 total costs

RO1 HL69136-01 - National Institute of Health Lung Epithelium-derived IL-6 in CD4+ T cell immune response PI: Mercedes Rincon, PhD Co-Investigator: Charles G. Irvin, PhD. (10% effort) 10/01/01-09/30/05 $4,000.000 total award

RO1 20815 - National Heart, Lung and Blood Institute Jerome A. Dempsey, Principal Investigator Charles G. Irvin, Research Associate 7/1/77 - 7/10/78 $195,000

F32 05784 - National Heart, Lung and Blood Institute Charles G. Irvin, Postdoctoral Fellow NSRA Fellowship 9/10/78 - 9/9/80 $65,000

R23 28025 - National Heart, Lung and Blood Institute Young Investigator Award Charles G. Irvin, Principal Investigator 3/1/82 - 2/28/85 $107,500

Boehringer - Boehringer Ingelheim Pharmaceuticals Reuben M. Cherniack and Charles G. Irvin, Co-investigators 1/84 - 2/86 $40,000

Purdue Frederick - Purdue Frederick Pharmaceuticals Charles G. Irvin, Principal Investigator 10/90 - 1992 $65,000

ALA-Colorado - American Lung Association of Colorado Charles G. Irvin, Principal Investigator 2/1/86 - 1/31/87 $8,000
PO1 36577 - National Heart, Lung and Blood Institute Gary L. Larsen, Principal Investigator Charles G. Irvin, Principal Investigator, Project 2 7/1/86 - 6/30/96 $150,000/year
Cortech - Evaluation of CP-1027B4 Aerosol in a Rat Bronchospasm Model Charles G. Irvin, Principal Investigator 5/92 - 5/93 $10,000

Fisons - Charles G. Irvin, Principal Investigator 4/91 - 4/93 $55,000

T-Cell Sciences - Effects of a Compliment Receptor Antagonist on an Animal Model of Asthma Charles G. Irvin, Principal Investigator 6/1/96 - 7/1/97 $30,000

National Jewish CIC - Charles G. Irvin, Principal Investigator 1/1/94 - 12/31/95 $52,880.00

1 N01-HR-16048 - National Heart, Lung and Blood Institute Childhood Asthma Management Program (CAMP) Stanley J. Szefler, Principal Investigator Co-Investigator: 10% effort 6/1/91 - 12/1/99 $12,553 (annual direct) $8,210 (annual indirect) (43%)

PO1 36577 - National Heart, Lung and Blood Institute Program Project Grant Inflammation, Airways Reactivity and Asthma Gary L. Larsen, Principal Investigator Charles G. Irvin, Co-Investigator: Project 2 (9.97% effort)Co-investigator: Project 3 (5% effort), 7/1/96 - 6/30/01 $12,013 (annual direct) $7,057 (annual indirect) (43%)

Glaxo-Wellcome - Early Intervention in Childhood Asthma Stanley Szefler, Principal Investigator Co-Investigator (25% effort)$31,383 (annual direct) $20,525 (annual indirect) (53%)

RO1 - National Heart, Lung and Blood Institute Symptom Perception in Pediatric Asthma Marianne Wamboldt, Principal Investigator Co-Investigator (5% effort)$6,277 (annual direct) $2,937 (annual indirect) (53%)

RO1 - National Heart, Lung and Blood Institute Biochemistry and Biology of 5-Lipoxygenase and Leukotrienes Colin Funk, Principal Investigator Co-Investigator (10% effort)7/1/97 - 6/30/01 $42,483 (annual direct) $22,856 (annual indirect) (53%)

RO1 HL60793 (N. Lee) - National Institute of Health Eosinophil effector functions in the lung Charles G. Irvin, Principal Investigator (10% effort) 1998 - 2001$1,317,060 total award

Glaxo-Wellcome -Physiologic Characteristics of the Lung Parenchyma in Near-Fatal Asthma Charles G. Irvin, Principal Investigator (10% effort) 7/1/96 - 6/30/98$52,881.87 (current annual direct)

Patent License (IL-12) $29,500 (current annual direct)$36,500 (Med) (current annual indirect)

RO1 HL56638 - National Heart, Lung and Blood InstituteAirway Fibrosis, Lung Mechanics and Hyperresponsiveness Charles G. Irvin, Principal Investigator (35% effort) 1998 - 2002 $172,967 (current annual direct) $91,673 (current annual indirect) (53%)

Awards and Honors

1978 Post Doctoral Fellowship American Lung Association
1978-1980 NRSA Fellowship National Institutes of Health
1980 NRA Travel Award Budapest, Hungary
1981-1984 Young Investigator Award National Institutes of Health, NHLBI
1983 La Société Canadienne de Récherches Cliniques; Schering Travel Award.

Publications

5Duan QL, Gaume BR, Hawkins GA, Himes BE, Bleecker ER, Klanderman B, Irvin CG, Peters SP, Meyers DA, Hanrahan JP, Lima JJ, Litonjua AA, Tantisira KG, Liggett SB.  Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med. accepted

Bosse Y, Riesenfeld EP, Pare PD, Irvin CG. It's not all smooth muscle: non-smooth-muscle elements in control of resistance to airflow. Annu Rev Physiol;72:437-62, 2010.  PMID:  20148684

Wu AC, Himes BE, Lasky-SU J, Litonjua A, Li L, Lange C, Lima J, Irvin CG, Weiss S.  Development of a Pharmacogenetic Predictive Test for Asthma:  Proof of Concept. Pharmacogenet Genomics 20:86-93, 2010.  PMID:  20032818

Neveu WA, Allard JL, Raymond DM, Bourassa LM, Burns SM, Bunn JY, Irvin CG, Kaminsky DA, Rincon M. Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function. Respir Res;11:28, 2010.  PMID:  20205953

Riesenfeld EP, Sullivan MJ, Thompson-Figueroa JA, Haverkamp HC, Lundblad LK, Bates JH, Irvin CG, Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. Respir Res;11: 22, 2010.  PMID:  20181256